Compound Target Indication (Combination) Stage of Development Partner
Clinical Programs
AEG35156 X-Linked Inhibitor of Apoptosis (XIAP) 2nd Line AML (High Dose Arac/Idarubicin) Randomized Phase 2  
    HCC (Sorafenib) Randomized Phase 2  
    CLL/B-Cell Lymphoma Phase I/2
AEG40826 (HGS1029) Inhibitor of Apoptosis Proteins (IAPs) Solid Tumors
Lymphoid Tumors
Phase I
Phase I
Preclinical Programs
AEGXXXXX Inhibitor of Apoptosis Proteins (IAPs) Inflammatory/Autoimmune Diseases Preclinical Development Candidate Selection